- GlaxoSmithKline
- Tesaro
- consumer-genetics company 23andMe.
Pharma giant GSK just made a $5.1 billion bet on a cancer drugmaker (GSK, TSRO)
Pharma giant GlaxoSmithKline just acquired cancer drugmaker Tesaro for $5.1 billion in a bid to bulk up its cancer pipeline.
GlaxoSmithKline is getting deeper into cancer drug development.
On Monday, the UK-based pharma giant said it had agreed to acquire Tesaro, a cancer drugmaker with a treatment for ovarian cancer, for $5.1 billion.
GSK has been working to refresh its research-and-development strategy. In 2017, GSK brought on Hal Barron, a former Genentech and Calico executive, as its chief scientific officer and president of R&D.
As part of that, the company made a $300 million investment in the consumer-genetics company 23andme. GSK also said in July that it planned to focus its research efforts on developing new treatments that act on the body's immune system.
"BRCA
Tesaro makes a cancer drug called Zejula, which is used to treat ovarian cancer.
Zejula isn't the only PARP inhibitor out there: Pfizer acquired one in its deal for Medivation, Clovis Oncology makes Rubraca, and AstraZeneca has Lynparza
JOIN OUR PULSE COMMUNITY!
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng